Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic Programs

Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic Programs

<i>Background and Objectives</i>: Wet age-related macular degeneration (wAMD) is a chronic, progressive disease of the central part of the retina. Standard treatment for wAMD consists of multiple intravitreal injections of anti-vascular endothelial growth factor drugs. The study goal was...

Full description

Bibliographic Details
Main Authors:	Małgorzata Figurska, Marek Rękas
Format:	Article
Language:	English
Published:	MDPI AG 2021-12-01
Series:	Medicina
Subjects:	wet age-related macular degeneration intravitreal injections aflibercept ranibizumab electronic registry
Online Access:	https://www.mdpi.com/1648-9144/58/1/42

Similar Items

Ranibizumab with transpupillary thermotherapy for clinical efficacy in wet age-related macular degeneration
by: Jia Li, et al.
Published: (2014-10-01)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
by: Dorota Luksa, et al.
Published: (2021-11-01)

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
by: Xiu-Xian Wang, et al.
Published: (2021-12-01)

Adding a Corticosteroid or Switching to Another Anti-VEGF in Insufficiently Responsive Wet Age-Related Macular Degeneration
by: Kaya C, et al.
Published: (2019-12-01)

Retinal function determined by flicker ERGs before and soon after intravitreal injection of anti-VEGF agents
by: Gaku Terauchi, et al.
Published: (2019-06-01)

Aflibercept monotherapy or bevacizumab first for diabetic macular edema
by: Avner Hostovsky, et al.
Published: (2024-01-01)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
by: Nudleman E, et al.
Published: (2016-06-01)

Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01)

Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation
by: Maruyama-Inoue M, et al.
Published: (2019-10-01)

Comparison of efficacy between Ranibizumab and Conbercept for wet age-related macular degeneration
by: Qiang Fan, et al.
Published: (2018-08-01)

Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration
by: Bekir Küçük, et al.
Published: (2018-04-01)

An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data
by: Dominic Muston, et al.
Published: (2018-12-01)

Management of Macular Edema Secondary to Branch Retinal Vein Occlusion in an Eye with Prior Vitrectomy and Lensectomy
by: Pankaj Malhotra, et al.
Published: (2014-10-01)

A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal
by: Rufino Silva, et al.
Published: (2017-06-01)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
by: Kaiser SM, et al.
Published: (2021-09-01)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01)

Factors Affecting Compliance to Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Age-Related Macular Degeneration
by: Onur Polat, et al.
Published: (2017-08-01)

Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
by: Flora Elwes, et al.
Published: (2018-01-01)

Intravitreal Aflibercept Treatment Strategies in Routine Clinical Practice of Neovascular Age-Related Macular Degeneration in Belgium: A Retrospective Observational Study
by: Joke Ruys, et al.
Published: (2020-09-01)

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
by: Laura García-Quintanilla, et al.
Published: (2019-07-01)

Effect of conbercept or ranibizumab in the treatment of wet age-related macular degeneration
by: Dawei Zhang, et al.
Published: (2019-01-01)

Curative effect of different drugs in treatment of senile wet macular degeneration
by: Zhi-Qin Zhang, et al.
Published: (2017-06-01)

Visual acuity loss associated with excessive “dry macula” in exudative age-related macular degeneration
by: Takahashi H, et al.
Published: (2018-02-01)

The Safety of Anti-VEGF Treatment, in the Context of the Retinal Nerve Fibre Layer, in Patients with Wet Age-Related Macular Degeneration: A Review
by: Małgorzata Wichrowska, et al.
Published: (2023-09-01)

Functional results one-year following the anti-VEGF therapy in macular pathology
by: Nicoleta Anton, et al.
Published: (2023-12-01)

Ranibizumab versus aflibercept for macular edema secondary to nonischemic central retinal vein occlusion in young adult patients
by: Ahmed A Amer, et al.
Published: (2022-01-01)

One-year results of switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab
by: Mahmoud Alaa Abouhussein, et al.
Published: (2021-01-01)

Intravitreal injection of Conbercept in the treatment of exudative age-related macular degeneration
by: Hong-Xia Niu, et al.
Published: (2018-09-01)

Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept
by: Agnieszka Nowosielska
Published: (2019-10-01)

Clinical Application of Intravitreal Aflibercept Injection for Diabetic Macular Edema Comparing Two Loading Regimens
by: Yoo-Ri Chung, et al.
Published: (2023-03-01)

Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration
by: Mehta N, et al.
Published: (2023-02-01)

Short-term results of early switch from Ranibizumab to Aflibercept in poor or non responder age related macular degeneration in clinical practice
by: Luciana de Sá Quirino-Makarczyk, et al.
Published: (2020-05-01)

Results of Intravitreal Ranibizumab Treatment for Exudative Age-Related Macular Degeneration
by: Umut Karaca, et al.
Published: (2012-01-01)

Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study
by: Benjamin Chi-Lan Yang, et al.
Published: (2019-01-01)

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
by: Junyeop Lee, et al.
Published: (2022-03-01)

Choroidal structural changes determined by the binarization method after intravitreal aflibercept treatment in neovascular age-related macular degeneration
by: Emine Temel, et al.
Published: (2021-08-01)

The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry
by: Oldrich Chrapek, et al.
Published: (2015-09-01)

Comparative study between ranibizumab and aflibercept in the management of macular edema caused by diabetes mellitus in age group more than 40 years
by: Abd El-Magid M Tag El-Din
Published: (2019-01-01)

XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration
by: Jean-François Korobelnik, et al.
Published: (2024-01-01)

THE EFFICACY AND SAFETY PROFILE OF ADVANCED THERAPY MEDICINAL PRODUCTS IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION
by: R. N. Alyautdin, et al.
Published: (2022-05-01)